Disclosures: The authors take full responsibility for the contents of this work, which do not represent the views of the U.S. Department of Education, the National Institutes of Health (NIH), the Department of Veterans Affairs, or the United States Government. R.T.A. has served as a consultant for PTC Therapeutics, Inc. A.C. serves as a consultant for GlaxoSmithKline. D.M.E. serves on the speakers bureau for and has received funding for travel and speaker honoraria from Athena Diagnostics, Inc.; he also serves as a consultant for Acceleron Pharma, HALO Therapeutics, AVI Biopharma, the Gerson Lehman Group, and Medacorp. J.M.F. serves on a scientific advisory board for Prosensa, serves on the editorial board of Neuromuscular Disorders, and serves/has served as a member of the CINRG Executive Committee and as a consultant for Prosensa, GlaxoSmithKline, Genzyme Corporation, PTC Therapeutics, Inc., and Acceleron Pharma. E.K.H. is a member of the CINRG Executive Committee, has served as a consultant for Genzyme Corporation and PTC Therapeutics, Inc., and has received travel assistance from Parent Project Muscular Dystrophy. E.P.H. has served on advisory committees for AVI BioPharma, Inc., as a consultant with the Gerson Lehman Group, Medacorp, and Lazard Capital, and is cofounder, board member, and shareholder of ReveraGen Biopharma. C.M.M. has served on advisory committees for PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., GlaxoSmithKline, Prosensa, HALO Therapeutics, Shire HGT, and Novartis AG. The remaining authors have no conflicts of interest to disclose.
The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
Article first published online: 6 MAY 2013
Copyright © 2013 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 48, Issue 1, pages 55–67, July 2013
How to Cite
Henricson, E. K., Abresch, R. T., Cnaan, A., Hu, F., Duong, T., Arrieta, A., Han, J., Escolar, D. M., Florence, J. M., Clemens, P. R., Hoffman, E. P., McDonald, C. M. and the CINRG Investigators (2013), The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve, 48: 55–67. doi: 10.1002/mus.23808
This study was funded by grants from the U.S. Department of Education/NIDRR (H133B031118, H133B090001), the U.S. Department of Defense (W81XWH-09-1-0592), the NIH (UL1RR031988, U54HD053177, UL1RR024992, U54RR026139, 2U54HD053177, G12RR003051, 1R01AR061875, RO1AR062380), and Parent Project Muscular Dystrophy.
C.M.M. is the study's principal investigator; E.K.K., R.T.A., A.C., and C.M.M. are study chairs.
- Issue published online: 21 JUN 2013
- Article first published online: 6 MAY 2013
- Accepted manuscript online: 6 FEB 2013 10:15AM EST
- Manuscript Accepted: 30 JAN 2013
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!